Evoke Pharma, Inc. (NASDAQ:EVOK) Short Interest Update

Evoke Pharma, Inc. (NASDAQ:EVOK) was the recipient of a large drop in short interest in June. As of June 30th, there was short interest totalling 11,300 shares, a drop of 54.4% from the June 15th total of 24,800 shares. Approximately 0.2% of the shares of the stock are short sold. Based on an average daily volume of 27,500 shares, the short-interest ratio is currently 0.4 days.

Evoke Pharma Trading Up 1.8 %

Shares of EVOK stock traded up $0.01 on Friday, reaching $0.58. 20,438 shares of the stock were exchanged, compared to its average volume of 43,801. Evoke Pharma has a one year low of $0.40 and a one year high of $1.77. The stock has a 50 day moving average price of $0.50 and a 200 day moving average price of $0.62.

Evoke Pharma (NASDAQ:EVOK) last posted its quarterly earnings results on Tuesday, May 14th. The specialty pharmaceutical company reported ($0.17) earnings per share (EPS) for the quarter. Evoke Pharma had a negative return on equity of 4,908.09% and a negative net margin of 116.75%. The company had revenue of $1.74 million during the quarter.

Analyst Ratings Changes

Separately, StockNews.com assumed coverage on shares of Evoke Pharma in a research report on Sunday, July 7th. They set a “sell” rating on the stock.

Evoke Pharma Company Profile

Evoke Pharma, Inc, a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults.